Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Berge EM, Aisner DL, Doebele RC. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thorac Oncol. 2013 Sep; 8(9):e83-4.